Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05398640 | Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release | available | — | — | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 20, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT06326411 |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors(NST-628) |
| recruiting |
| Phase 1 |
| 230 |
| Nested Therapeutics, IncINDUSTRY |
| 2 |
| Apr 20, 2026 |
| clinicaltrials |
| NCT07288203 | A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma | active not recruiting | Phase 2 | 100 | Iovance Biotherapeutics, Inc.INDUSTRY | 4 | Apr 20, 2026 | clinicaltrials |
| NCT02713269 | Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03881488 | Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | completed | Phase 1 | 100 | Compass TherapeuticsINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04474301 | Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic | recruiting | — | 1,152 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT05026983 | Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases | recruiting | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06660420 | Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) | recruiting | Phase 1 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06708663 | HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 124 | Hangzhou Hanx Biopharmaceuticals, Ltd.INDUSTRY | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07223424 | Patient Preference for Subcutaneous vs. Intravenous Immune Therapy(PSI-Immune) | recruiting | Phase 2 | 880 | Diwakar DavarOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01955460 | Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma | active not recruiting | Phase 1 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04693377 | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial | recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05377957 | Prospective Registration Of Patient Data and Quality of Life in Eye Melanoma Patients(PROQEM) | active not recruiting | — | 500 | Leiden University Medical CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05856565 | Generation of an Artificial Intelligence Algorithm Based on the Analysis of Melanoma Peri-scar Dermatoheliosis, as a Predictive Factor of Response to Anti-PD-1(HELIOPREDICT) | recruiting | — | 700 | Nantes University HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07530887 | NO Re-excision MelanomA - NORMA 2(NORMA-2) | recruiting | Phase 3 | 1,749 | Marieke GoodijkOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07531121 | ctDNA for Risk Stratification in Melanoma | active not recruiting | — | 296 | Herlev and Gentofte HospitalOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03348891 | TNF in Melanoma Patients Treated With Immunotherapy(MELANFα) | completed | N/A | 60 | Institut Claudius RegaudOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT02656706 | Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma | active not recruiting | Phase 2 | 22 | Brown UniversityOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05423262 | A Study of TRK-950 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 49 | Toray Industries, IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT05461430 | Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)(TraveraRTGx) | completed | — | 72 | Travera IncINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06216938 | RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis | recruiting | Early Phase 1 | 25 | Yana NajjarOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06362369 | A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | recruiting | Phase 1 / Phase 2 | 126 | 7 Hills Pharma, LLCINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06753136 | Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype | recruiting | N/A | 24 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07022457 | UK ENcorafenib and BInimetinib Real-world Study in Melanoma(UK-EnBiRiM) | active not recruiting | — | 50 | Pierre Fabre LtdINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT03699995 | MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma | terminated | N/A | 17 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06099782 | A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | active not recruiting | Phase 2 | 147 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Apr 8, 2026 | clinicaltrials |
| NCT07517653 | Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma | not yet recruiting | Phase 2 | 70 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 8, 2026 | clinicaltrials |
| NCT02668770 | Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies | terminated | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05289193 | CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma | active not recruiting | Phase 2 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02816021 | Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05105100 | Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma | completed | — | 25 | University of California, San FranciscoOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05170334 | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05704933 | Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases | completed | Early Phase 1 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | active not recruiting | Phase 1 | 40 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511036 | PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05496686 | Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | active not recruiting | Phase 1 | 16 | Modulation Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06694571 | Sun Protection and Tanning Awareness in Rural Schools(STARS) | completed | N/A | 38 | University of UtahOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05628883 | Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma | completed | Phase 1 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT05148325 | Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT4706 in Advanced Solid Tumors | completed | Phase 1 | 28 | Bio-Thera SolutionsINDUSTRY | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | recruiting | Phase 2 | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT06861647 | iSITE: Investigation of Somatic Alterations in Tumours of the Eye(iSITE) | completed | — | 58 | The Wellcome Sanger InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07506447 | The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma | completed | — | 68 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT01840007 | Pilot Study Evaluating the Efficacy and Safety of Metformin in Melanoma | completed | Phase 2 | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02133222 | Circulating Cell-free DNA in Metastatic Melanoma Patient: Mutational Analyses in Consecutive Measurement Before and After Chemotherapy(AMMAM) | completed | N/A | 22 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05130177 | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | active not recruiting | Phase 2 | 8 | Diwakar DavarOTHER | 1 | Mar 31, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 20, 2026source: clinicaltrials